{"id":113507,"date":"2021-05-04T12:03:22","date_gmt":"2021-05-04T12:03:22","guid":{"rendered":"https:\/\/fin2me.com\/?p=113507"},"modified":"2021-05-04T12:03:22","modified_gmt":"2021-05-04T12:03:22","slug":"pfizer-plans-to-file-for-full-fda-approval-of-covid-vaccine-at-the-end-of-this-month","status":"publish","type":"post","link":"https:\/\/fin2me.com\/business\/pfizer-plans-to-file-for-full-fda-approval-of-covid-vaccine-at-the-end-of-this-month\/","title":{"rendered":"Pfizer plans to file for full FDA approval of Covid vaccine at the end of this month"},"content":{"rendered":"

Pfizer said Tuesday it plans to file for full U.S. approval of its Covid-19 vaccine with German drugmaker BioNTech at the end of this month. If the FDA signs off, the company will be able to market the shot directly to consumers.<\/p>\n

In releasing its first-quarter financial results, the company also reported $3.5 billion in first-quarter sales of its Covid-19 vaccine and reported earnings and revenue that beat Wall Street's expectations.<\/p>\n

Here's how Pfizer did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:<\/p>\n